Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976859 | 0.88 | ACSS2 (0.53) | ACSS2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL16587410 | 0.84 | SLC22A12 (0.56) | ACSS2SLC22A12 | |
| SCHEMBL6169381 | 0.80 | ACSS2 (0.52) | ACSS2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL11976860 | 0.79 | KDM4E (0.54) | ACSS2TP53ALDH1A1APEX1 | |
| SCHEMBL11977348 | 0.74 | SLC22A12 (0.58) | SLC22A12CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL16752300 | 0.74 | SLC22A12 (0.74) | SLC22A12 | |
| SCHEMBL6170515 | 0.73 | SLC22A12 (0.58) | ACSS2SLC22A12 | |
| SCHEMBL4048200 | 0.72 | CYP2C9 (0.63) | CYP2C9CYP2C19CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL11975818 | 0.72 | SLC22A12 (0.62) | SLC22A12MEN1KMT2A | |
| SCHEMBL16587411 | 0.72 | KDM4E (0.56) | ACSS2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| WO-2012102405-A1 | RING-FUSED COMPOUND | 佐藤製薬株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | ACSS2 1340/4885SLC22A12 394/4885CYP2C9 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.